The invention relates to the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma. The invention furthermore relates to a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500 μl urine is indicative for transitional cell carcinoma and a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.
